Literature DB >> 10530421

A successful combination of plasma exchange and intravenous cyclophosphamide in a patient with a refractory thrombotic thrombocytopenic purpura.

P Zappasodi, A Corso, C Castagnola, M Tajana, M Lunghi, C Bernasconi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10530421     DOI： 10.1111/j.1600-0609.1999.tb01893.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  5 in total

Review 1.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

Review 2.  Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.

Authors:  Nay M Tun; Gina M Villani
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

3.  Postoperative thrombotic thrombocytopenic purpura after aortofemoral bypass.

Authors:  Naba R Mainali; Madan R Aryal; Madan Badal; Vijaya R Bhatt; Richard Alweis
Journal:  J Community Hosp Intern Med Perspect       Date:  2013-01-07

4.  Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era.

Authors:  Sowmya Goranta; Smit S Deliwala; Tarek Haykal; Ghassan Bachuwa
Journal:  BMJ Case Rep       Date:  2020-06-11

Review 5.  Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Ashley Hanlon; Ara Metjian
Journal:  Ther Adv Hematol       Date:  2020-02-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.